Notice of NIDDK Participation in RFA-EB-22-002 "HEAL Initiative: Translational Development of Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed)"
Notice Number:
NOT-DK-22-030

Key Dates

Release Date:

September 22, 2022

Related Announcements

RFA-EB-22-002 - HEAL Initiative: Translational Development of Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed)

Issued by

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Purpose

This notice informs potential applicants that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) will participate in RFA-EB-22-002,

"HEAL Initiative: Translational Development of Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed)" beginning with the November 14, 2022 application due date.

NIDDK will support the development of clinical-grade prototypes intended for use as safe, effective, and non-addictive device-based technologies and approaches to treat pain or opioid use disorder (OUD) associated with the diseases and conditions within its mission. NIDDK strongly encourages potential applicants to contact program staff for assistance in the early stages of developing applications.

The following sections of RFA-EB-22-002 have been modified (shown in bold italics) to reflect NIDDK's paricpation in this RFA:

Part 1. Overview Information

Components of Participatng Organizations

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

National Center for Complimentary and Integrative Health (NCCIH)

National Eye Institute (NEI)

National Institute on Aging (NIA)

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institute of Dental and Craniofacial Research (NIDCR)

National Institute on Drug Abuse (NIDA)

National Institute of Neurological Disorders and Stroke (NINDS)

National Cancer Institute (NCI)

Assistance ListingNumber(s)

Currently Reads:

93.286, 93.213, 93.846, 93.395, 93.393, 93.867, 93.273, 93.853, 93.121, 93.866, 93.865

Modified to Read (changes shown in bold italics):

93.286, 93.213, 93.846, 93.395, 93.393, 93.867, 93.273, 93.853, 93.121, 93.866, 93.865, 93.847

Section VII. Agency Contacts

Scientific/Research Contact(s)

Dana K. Andersen, M.D.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Telephone: 410-868-0638

Email: dana.andersen@nih.gov

Financial/Grants Management Contact(s)

Elizabeth Gutierrez

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Telephone: 301-594-8844

Email: gutierrezel@niddk.nih.gov

All other aspects of this RFA remain unchanged.

Inquiries

Please direct all inquiries to:

Dana K. Andersen, M.D.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Telephone: 410-868-0638

Email: dana.andersen@nih.gov